Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by KayakerBCon Jun 23, 2017 2:02pm
264 Views
Post# 26398904

Resetting the BS....

Resetting the BS....I see DigiScammer hasn't posted today.  No doubt he's working on some new BS.  Like (in his best Arnold voice):

"This is PUUUUUUUUUNY!  This shows a lack of confidence in BTI.  Why MD didn't buy 500,000 shares yesterday!!!"

Oh well, DigiScammer can always go back to reposting and reposting old news.  Like yesterday, he reposted this YEAR-OLD article on Herceptin and the heart.  

He's trying again after posting this bogus scare tactic just 3 weeks ago. 

This particular BS is ironic because he doesn't realize that using Transcend to transport trastuzumab across the BBB results in relative reduced distribution to the heart (as I posted in response to his BS post 3 weeks ago).

P97-antibody conjugates and methods of use
US 20130183368 A1

Abstract

The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.

....FIG. 10A shows the tissue/blood ratio of p97-trastuzumab conjugate for a variety of tissues. The ratios do not vary much between the two and eight hour time points; however, the ratio (levels) of conjugate in heart tissue are significantly lower than other tissues (e.g., about 10× lower that lung and liver tissues)....

.... Further, because of the reduced distribution to heart tissues relative to other tissues, these data suggest that conjugation to p97 might reduce the cardiotoxic effects of antibodies such as trastuzumab....
Bullboard Posts